News & Updates

Treatment with pemafibrate in patients with type 2 diabetes mellitus (T2DM) yields more favourable effects on lipid profile, as well renal function, as compared with conventional fibrates, a study has found.

Type 2 diabetes (T2D) patients on sodium-glucose cotransporter 2 (SGLT2) inhibitors appear to be at lower risk of dry eye disease (DED) compared with their counterparts who are receiving glucagonlike peptide-1 receptor agonists (GLP-1 RAs), as shown in a study.

Each additional optimal modifiable factor among women with a history of gestational diabetes mellitus (GDM) significantly contributes to a reduction in type 2 diabetes (T2D) risk, suggests a recent study. These associations are also present among individuals who are overweight/obese or are at greater genetic susceptibility to T2D.

In type 2 diabetes (T2D) patients with constipation, treatment with elobixibat alleviates constipation while improving glucose metabolism and lowering serum low-density lipoprotein cholesterol (LDL-C) and arachidonic acid (AA) levels, according to the results of a single-arm pilot study.

The ratio between gamma-glutamyl transferase (GGT) and high-density lipoprotein cholesterol (HDL-c) shares a positive and nonlinear relationship with incident diabetes, reports a recent Japan study.

PCSK9 inhibition with evolocumab produces clinically meaningful and sustained reductions in certain lipid parameters in a predominantly Arabic population of individuals with familial hypercholesterolaemia (FH) and other non-FH indications, according to a study.

An intensive weight-loss intervention has failed to substantially improve the treatment outcomes among obese patients with nonalcoholic fatty liver disease (NAFLD), reports a recent study.

Patients with type 2 diabetes (T2D) can benefit from a dietitian-led intensive dietary intervention, including frequent dietary education, which helps promote more healthful eating patterns, a recent study has found.

The presence of erectile dysfunction (ED) does not appear to confer an increased risk of cardiovascular disease (CVD) and mortality in men with diabetes mellitus (DM), with comparable risk of adverse cardiovascular events among users and nonusers of phosphodiesterase-5 inhibitors (PDE5-Is), which are used to manage ED, according to a study.